News from Vantia Therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Oct 03, 2017, 07:00 ET Vantia Therapeutics Announces Positive Results From its Phase III EQUINOC Study, a Pivotal Trial with Fedovapagon for the Treatment of Nocturia in Men with Benign Prostatic Hyperplasia

Vantia Therapeutics announces positive top-line data from a pivotal Phase III trial investigating the efficacy and safety of fedovapagon...


Jul 06, 2011, 04:00 ET Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds

Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need, today...


Feb 02, 2010, 06:35 ET Vantia Therapeutics' Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia

Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today...


Oct 06, 2009, 06:58 ET Vantia Therapeutics' VA111913 Enters Phase II Proof-of-Concept Trials for Dysmenorrhoea Phase I Results Show VA111913 to be Safe and Well Tolerated

Vantia Therapeutics today announces that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered...


Jun 29, 2009, 04:57 ET Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia

Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets,...


Apr 21, 2009, 06:07 ET Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs

Vantia Therapeutics, a company developing novel small molecule drugs targeting large underserved medical markets, today announces the appointment...


Mar 24, 2009, 07:04 ET Vantia Therapeutics' Pipeline Continues to Mature

- VA106483 Completes Phase IIa Trial and VA111913 Completes Phase I Dosing Vantia Therapeutics, a company focusing on first-in-class therapies...